

# ARI PANZER

Washington, DC  
(516) 732-6349

<https://www.linkedin.com/in/ari-panzer-34b414129/>  
[apanzer@winstonfellowship.org](mailto:apanzer@winstonfellowship.org)

## SUMMARY

---

Skilled policy analyst with five years of experience in domestic and global health policy research. Thorough training in and experience with quantitative and qualitative analysis, strategic thinking, project management, consensus-building, effective oral and written communication, data visualization, and problem solving. Committed to addressing the social drivers of health, reducing health disparities, and understanding the influence of climate change on population health.

## EDUCATION

---

### Duke University, Sanford School of Public Policy

Durham, NC

Master of Public Policy

Aug 2021 - May 2023

- Duke Margolis Scholar in Health Policy and Management
- 2022 – 2023 David A. Winston Health Policy Scholar
- Relevant Coursework: policy analysis, statistics, economics, econometrics, health policy analysis
- Client projects with the National Academy for State Health Policy, myFutureNC, and the North Carolina Department of Health and Human Services
- MPP Service Award for outstanding contributions through service to the MPP Program and the Sanford School of Public Policy, May 2023

### Tufts University

Medford, MA

Bachelor of Science in Psychology and Community Health, *summa cum laude*

Aug 2013 - May 2017

- Senior Thesis with Highest Honors: “Pain perception and treatment recommendations: how do medical professionals make pain treatment decisions?”
- Joanne Mary Sullivan Prize for excellence and promise in the study of psychology, May 2017

## EXPERIENCE

---

### David A. Winston Health Policy Fellowship

Washington, DC

David A. Winston Health Policy Fellow (40 hours/week)

June 2023 – Present

### Duke University, Sanford School of Public Policy

Durham, NC

Teaching Assistant – Policy Analysis II (12 hours/week)

Jan 2023 – May 2023

- First point-of-contact for student inquiries
- Reviewed and edited student deliverables
- Counseled students on interpersonal group conflicts and team dynamics
- Advised students on formulating policy questions, improving writing, and structuring memos

Teaching Assistant – Policy Analysis I (12 hours/week)

Aug 2022 – Dec 2023

- Facilitated class discussions on policy analysis theory and practice
- Reviewed and graded policy memo assignments
- Routinely met with students to improve writing and organization skills

### Government Accountability Office (GAO)

Washington, D.C.

Analyst Student Intern: (40 hours/week)

May 2022 – Aug 2022

- Education, Workforce, and Income Security Team
- Led an objective on institutional strategies to promote and maintain faculty diversity
- Reviewed documentation from Education, Equal Employment Opportunity Commission, and DOJ and developed follow-up questions for the agencies
- Presented in meetings with directors, methodologists, and General Council

### Duke University, Sanford School of Public Policy

Durham, NC

Graduate Assistant – Academic Programs (12 hours/week)

Jan 2022 – May 2022

- Analyzed student performance data in core courses to identify gaps in preparedness
- Identified alternative existing conditional admittance preparation courses

**CEVR, Tufts Medical Center**

Part-Time Researcher (Per-Diem)

- Collected, cleaned, and formatted data for upload to the SPEC database
- Identified new data sources and designed collection tools
- Reviewed manuscript drafts

**Boston, MA**

Aug 2021 – May 2023

**CEVR, Tufts Medical Center**

Project Manager (40 hours/week)

- Managed and coordinated 5 – 10 internal and external research projects relating to health coverage variation and patient access disparities
- Identified emerging issues impacting patient access and health insurance coverage
- Analyzed and manipulated large datasets to answer policy questions and draft manuscripts
- Facilitated meetings, mentored a team of four research assistants, trained team members
- Developed research questions, study designs, and project plans

**Boston, MA**

Mar 2020 – Aug 2021

Research Associate (40 hours/week)

- Maintained a database of health plan specialty drug coverage decisions
- Organized data collection for triannual database updates
- Documented data collection and management processes and identified areas for improvement
- Tracked pharmaceutical development and health insurance coverage regulatory policies
- Led quantitative analyses examining domestic and global health policy topics

June 2019 – Mar 2020

Research Assistant (40 hours/week)

- Reviewed economic and public health literature
- Drafted manuscripts, memos, abstracts, grants, and IRB protocols
- Extracted cost-effectiveness and utility weight data from published articles
- Analyzed cost-effectiveness registry data to identify high-value interventions and literature gaps

June 2017 – June 2019

**LEADERSHIP AND SERVICE**

---

**President and Co-Editor-in-Chief**, *Sanford Journal of Public Policy*, May 2022 – May 2023**Mentor**, Duke Student Collaborative on Health Policy (SCOHP) Passport Program, April 2022 – Present**Mentor**, Sanford Reading Applicants through Mentorship Pairings Program, Nov 2021 – Present**Volunteer**, Get Out the Vote, Fall 2018 & Fall 2020**Co-Manager**, Tufts University Quidditch, April 2015 – May 2017**Volunteer**, Ears4Peers Anonymous Student Confidential Hotline, October 2014 – May 2017**ADDITIONAL SKILLS**

---

**Computer Skills:** Stata, R, Tableau, Qualtrics, MS Suite, Advanced Excel**Foreign Language Skills:** Proficient in Spanish**Disciplines:** Black belt in Shotokan Karate**PUBLICATIONS**

---

- **Panzer AD**, Ingham M, Martin S, Chambers JD. The association between US Food and Drug Administration expedited review designations and health plan specialty drug coverage. *The Journal of Managed Care & Specialty Pharmacy*. 2023 May;29(5):464-471.
- Chambers JD, Enright DE, **Panzer AD**, Cohen JT, Ollendorf DA, Neumann PJ. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions. *The Journal of Managed Care & Specialty Pharmacy*. 2023 Mar;29(3):257-64.
- **Panzer AD**, Enright DE, Graff J, Chambers JD. Characterizing health plan evidence review practices. *The Journal of Managed Care & Specialty Pharmacy*. 2022 Sept;28(9):1053-8.
- **Panzer AD**, Margaretos NM, Bridger N, Osani MC, Lai RC, Chambers JD. Patients' access to 2018 FDA approved drugs one year post-approval. *The American Journal of Managed Care*. 2022 Apr 1;28(4):e153-e156.

- Lenahan K, **Panzer AD**, Gertler R, Chambers JD. Use of prescriber requirements among US commercial health plans. *The Journal of Managed Care & Specialty Pharmacy*. 2021 Dec;27(12):1757–62.
- Margaretos NM, Patel AM, **Panzer AD**, Lai RC, Whiteley J, Chambers JD. Variation in access to hemophilia treatments in the United States. *Journal of Medical Economics*. 2021 Jan 1;24(1):1143–8.
- D’Cruz B, Graff JS, **Panzer A**, Chambers JD. Limited role of patient input in specialty drug coverage policies. *The Journal of Managed Care & Specialty Pharmacy*. 2021 Aug;27(8):1067–76.
- Margaretos NM, **Panzer AD**, Lai RC, Sanon M, Michalopoulos E, Redmond AM, Moghadam R, Chambers JD. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease. *The Journal of Managed Care & Specialty Pharmacy*. 2021 Sep;27(9):1221–9.
- **Panzer AD**, Emerson JG, D’Cruz B, Patel A, Dabak S, Isaranuwachai W, Teerawattananon Y, Ollendorf DA, Neumann PJ, Kim DD. Growth and capacity for cost-effectiveness analysis in Africa. *Health Economics*. 2020;29:945–954.
- **Panzer AD**, Margaretos NM, Lai RC, Enright DE, Chambers JD. What types of real-world evidence studies do US commercial health plans cite in their specialty drug coverage decisions? *Pharmacoepidemiology and Drug Safety*. 2020;29(10):1307–1311
- Chambers JD, Lai RC, Margaretos NM, **Panzer AD**, Cohen JT, Neumann PJ. Coverage for biosimilars vs reference products among US commercial health plans. *JAMA*. 2020;323(19):1972–1973.
- Chambers JD, **Panzer AD**, Pope EF, Graff JS, Neumann PJ. Variation in the evidence commercial health plans cite in their specialty drug coverage policies. *Health Affairs*. 2019;38(11):1882–1886.
- Chambers JD, **Panzer AD**, Kim DD, Margaretos NM, Neumann PJ. Variation in US Private Health Plans’ Coverage of Orphan Drugs. *American Journal of Managed Care*. 2019;25(10):508–512.
- Emerson J, **Panzer A**, Cohen JT, Chalkidou K, Teerawattananon Y, Sculpher M, Wilkinson T, Walker D, Neumann PJ, Kim DD. Adherence to the iDSI reference case among published cost-per-DALY averted studies. *PloS one*. 2019;14(5):e0205633.
- Chambers JD, **Panzer AD**, Neumann PJ. Variation in the use of step therapy protocols across US health plans. *Health Affairs Blog*. 2018.
- Neumann PJ, Anderson JE, **Panzer AD**, Pope EF, D’Cruz BN, Kim DD, Cohen JT. Comparing the cost-per-QALYS gained and cost-per-DALYs averted literatures. *Gates Open Research*. 2018;2:5.

## PRESENTATIONS

- **Panzer AD**, Ingham M, Martin S, Chambers JD. The association between FDA expedited approval designations and health plan specialty drug coverage issuance speed. AMCP Nexus 2022, National Harbor, Maryland, October 11-14, 2022.
- **Panzer A**, Margaretos N, Chambers J. Characterizing health plan evidence review practices: an empirical analysis. AMCP Nexus 2020 Virtual, October 19-23, 2020.
- Margaretos N, **Panzer A**, Chambers J. Substantial variation in payer coverage policies for rare neuromuscular disease treatments. AMCP Nexus 2020 Virtual, October 19-23, 2020.
- **Panzer A**, Margaretos N, Lai R, Enright DE, Chambers J. Do health plans cite real-world evidence in their specialty drug coverage policies? An empirical analysis. 2020 International Society for Pharmacoeconomics and Outcomes Research Virtual Program, May 18-20, 2020.
- **Panzer A**, Margaretos N, Neumann PJ, Kim DD, Chambers J. Are health plans more likely to restrict coverage of orphan drugs with larger budget impacts? 2019 International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22, 2019.
- D’Cruz B, **Panzer A**, Graff J, Chambers J. Patients have little, if any, input into commercial health plan specialty drug coverage policy development. 2019 International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22, 2019.
- Margaretos N, **Panzer A**, Neumann PJ, Chambers J. Do health plans cover orphan and non-orphan drugs differently? An empirical analysis. 2019 International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22, 2019.